Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Anu Aiyengar To Solely Lead JPMorgan’s Global M&A – $JNJ $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, JPMorgan Chase & Co (JPM) named its veteran of more than two decades Anu Aiyengar as the sole lead of its global mergers and acquisitions franchise after co-head Dirk Albersmeier resigned from the role. Aiyengar has led the bank’s M&A franchise after she was promoted to lead alongside Dirk Albersmeier in 2020.

The announcement came in an internal memo stating, “Albersmeier will take on a new wholly client and transaction-focused role within JPMorgan. Going forward, Anu will be the sole head of our global M&A business and Dirk will focus exclusively on providing our clients with first-class M&A advice and continuing to mentor the next generation of M&A leaders.”

JPMorgan Chase & Co (JPM) is a global financial service leader in investment banking, financial services for consumers and businesses, financial transaction processing, asset management, and commercial banking. To learn more about JPMorgan Chase & Co. (JPM) and to continue to track its progress please visit the Vista Partners JPMorgan Chase & Co. Coverage Page.

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

(Read Original Story: UPDATE 1-JPMorgan names Anu Aiyengar sole head of global M&A in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us